Merck Reports Solid Q3 Sales Driven by Oncology and WINREVAIR

Wall Street woke up to solid third-quarter figures from Merck & Co., Inc., which reported total worldwide sales of $18.1 billion—marking a 5% increase year-over-year, or 4% excluding foreign exchange impacts. Reading the raw financial disclosures and listening to the investor conference calls, analysts noted that key growth drivers easily outpaced consensus estimates, even as the pharmaceutical giant faces mounting questions regarding patent expiries on its flagship oncology assets.

The Bottom Line:

• Total worldwide sales reached $18.1 billion for the third quarter of 2026, beating Wall Street consensus projections despite currency headwinds.
• Non-GAAP EPS landed at $2.49, incorporating a $0.12 per share one-time charge tied to a global licensing agreement with SciBrunch.
• Management narrowed and raised its full-year 2026 sales guidance to a range between $66.8 billion and $67.3 billion, while lifting non-GAAP EPS expectations to $2.77 to $2.82.

Keytruda Portfolio Drives Financial Resilience with Strong Quarterly Sales

The core of Merck’s financial resilience continues to rest on its oncology portfolio. KEYTRUDA and KEYTRUDA QLEX generated a combined $8.6 billion in sales during the quarter, representing a 6% increase. The newer subcutaneous injection formulation, KEYTRUDA QLEX, contributed $830 million in sales following its September 2025 rollout and the acquisition of a permanent J-code in April. Executives are targeting a 30% to 40% adoption rate in the United States by the end of 2027.

CEO Robert Davis addressed looming patent cliffs by characterizing the upcoming expiration of KEYTRUDA exclusivity as “more of a hill than a cliff.” Management pointed to a broad pipeline of more than 20 new products representing greater than $70 billion in commercial opportunity. CFO Caroline Litchfield emphasized during an investor call that 2027 will remain another year of investment to support these expanding lines.

Winrevair Sales Surge Past Analyst Estimates as Gardasil Rebounds

Beyond oncology, pulmonary arterial hypertension treatment WINREVAIR emerged as a standout performer, posting $694 million in quarterly sales—a 93% surge year-over-year. BMO Capital Markets noted that this rapid uptake exceeded analyst estimates by roughly 7%, driven by label expansions such as the Phase 3 HYPERION study results. Meanwhile, GARDASIL brought in approximately $2 billion, rebounding from previous inventory hurdles in international markets.

Not every legacy product shared in the upside. JANUVIA/JANUMET fell 31% last quarter.

Operating Expenses and the Main Street Portfolio Impact

R&D expenses were driven by clinical development spending and a $400 million charge associated with the SciBrunch agreement.

While analysts have adjusted near-term earnings estimates to account for R&D investments and restructuring costs, the consensus view treats Merck’s diversified pipeline as a dependable defensive anchor amid macroeconomic volatility. The company’s investment-grade credit rating preserves ample liquidity for future business development.

Capital Guidance Adjustments for the Final Quarter

Reflecting third-quarter outperformance, leadership tightened the financial parameters for the remainder of the fiscal year. The revised full-year sales forecast now sits between $66.8 billion and $67.3 billion, while the non-GAAP EPS range moves up to $2.77 to $2.82. Detailed financial documentation and supplementary earnings schedules remain accessible via official regulatory disclosures on SEC.gov.

Disclaimer: The information provided in this article is for educational and market analysis purposes only and does not constitute financial, investment, or legal advice. Always consult with a certified financial professional before making investment decisions.

More on this story: Boston Scientific Reports Q3 2026 Financial Results and Sales Growth

More on Reports: Anthropic Reports $16.8 Billion Q3 Revenue Ahead of Expected IPO